Crossmark

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1038/s41523-024-00666-y

Published Online: 2024-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hurvitz, Sara A. https://orcid.org/0000-0001-7808-7191
Bardia, Aditya

Punie, Kevin

Kalinsky, Kevin https://orcid.org/0000-0002-3113-7902
Carey, Lisa A. https://orcid.org/0000-0003-2388-4649
Rugo, Hope S. https://orcid.org/0000-0001-6710-4814
Diéras, Véronique https://orcid.org/0000-0001-8094-4738
Phan, See

Delaney, Rosemary

Zhu, Yanni

Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
License Information

Text and Data Mining valid from 2024-07-09

Version of Record valid from 2024-07-09
More Information

Article History

First Online: 9 July 2024